Clinical Trials Logo

Joint Hypermobility Syndrome clinical trials

View clinical trials related to Joint Hypermobility Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05633225 Completed - Clinical trials for Hypermobile Ehlers-Danlos Syndrome

Central Sensitization and Physical Activity in Adolescents With HSD/hEDS

Start date: November 25, 2022
Phase:
Study type: Observational

Hypermobility Spectrum Disorder and hypermobile Ehlers-Danlos Syndrome (HSD/hEDS) is under-recognized and poorly understood and its management is therefore not clear. The goal of this study is to better understand pain and its impact on function in the daily activities of adolescents with Hypermobility Spectrum Disorder and/or hypermobile Ehlers-Danlos Syndrome. This study will explore the presence of the pain sensitivity status after physical exercise as well as movement behaviour in adolescents with HSD/hEDS compared to a healthy control group.

NCT ID: NCT04279990 Completed - Clinical trials for Functional Dyspepsia

Assessment of Gastric Motility on Funtional Dyspepsia and Joint Hypermobility Syndrome

Start date: July 4, 2014
Phase:
Study type: Observational

Functional dyspepsia (FD) is defined as the presence of gastroduodenal symptoms in the absence of organic disease that is likely to explain the symptoms. Joint hypermobility (JH) refers to the increased passive or active movement of a joint beyond its normal range. Recent reports have highlighted the co-existence of FD with Ehlers-Danlos syndrome type III or hypermobility type (EDSIII). The association between FD and EDS III, and the underlying pathophysiological alterations, are poorly understood. We hypothesised that EDS III might influence gastroduodenal sensorimotor function, resulting in dyspeptic symptoms. Therefore, the aim of this study is to explore the impact of EDS III on gastric motility, nutrient tolerance and dyspeptic symptoms in patients with functional dyspepsia.Our aim is to study the prevalence of EDSIII in FD compared to healthy subjects (HS) and to study the impact of co-existing EDSIII on gastric motility, nutrient tolerance and dyspeptic symptoms in FD.